E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Diabetes Mellitus, Type 2 |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nutritional and Metabolic Diseases [C18] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10045242 |
E.1.2 | Term | Type II diabetes mellitus |
E.1.2 | System Organ Class | 10027433 - Metabolism and nutrition disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To confirm superiority of oral semaglutide at the maximum tolerated dose* (3 mg, 7 mg or 14 mg) versus placebo on glycaemic control in children and adolescents (age 10 to <18 years) with type 2 diabetes on a background treatment of metformin or basal insulin or both.
*maximum tolerated dose is defined as maximum dose level defined according to individual glycaemic response and tolerability as assessed by the investigator |
|
E.2.2 | Secondary objectives of the trial |
1. To assess and compare the efficacy of oral semaglutide at the maximum tolerated dose (3 mg, 7 mg or 14 mg) versus placebo on a background treatment of metformin or basal insulin or both on: A. Other parameters of glycaemic control B. Parameters of body composition C. Growth parameters D. Cardio-metabolic parameters 2. To assess and compare the safety and tolerability of oral semaglutide at the maximum tolerated dose (3 mg, 7 mg or 14 mg) versus placebo on a background treatment of metformin or basal insulin or both. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Informed consent from parent(s) or legally acceptable representative (LAR) and child assent from the subject obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial. - Male or female, aged 10 to less than18 years at the day of randomisation. - Glycosylated haemoglobin (HbA1c) 6.5−11.0 percent (47−97 mmol/mol) (both inclusive). - Diagnosed with type 2 diabetes mellitus according to the American Diabetes Association criteria and treated with: - stable metformin dose* or - stable metformin dose* and a stable dose of basal insulin** or - stable dose of basal insulin** *stable metformin dose is defined as at least 1000 mg daily or the maximum tolerated dose for 56 days or longer prior to screening. **stable dose of basal insulin is defined as basal insulin treatment more than or equal to 30 days prior to screening, compared to the dose at screening, dose adjustments of plus or minus 25 percent are allowed. |
|
E.4 | Principal exclusion criteria |
- Diagnosis of type 1 diabetes. - Maturity onset diabetes of the young (MODY). - Positive insulinoma associated-protein 2 (IA-2) antibodies or anti-glutamic acid decarboxylase (anti-GAD) antibodies. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Change in glycosylated haemoglobin (HbA1c) (%-point and mmol/mol) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
From baseline (week 0) to week 26 |
|
E.5.2 | Secondary end point(s) |
1. Change in HbA1c (week 52) 2. Change in fasting plasma glucose (FPG) 3. Change in body mass index (BMI) standard deviation score (SDS) 4. Change in body weight (kg) 5. Change in body weight (relative change in %) 6. Change in waist circumference 7. Change in BMI percentile (age and gender adjusted) 8. Change in systolic and diastolic blood pressure 9. HbA1c <7.0% (53 mmol/mol) (yes/no), American Diabetes Association (ADA) target and International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines from 2018 (week 26) 10. HbA1c ≤6.5% (48 mmol/mol) (yes/no), American Association of Clinical Endocrinologists (AACE) target (week 26) 11. HbA1c <7.0% (53 mmol/mol) (yes/no), ADA target and ISPAD guidelines from 2018 (week 52) 12. HbA1c ≤6.5% (48 mmol/mol) (yes/no), AACE target (week 52) 13. Time to additional anti-diabetic medication 14. Time to rescue medication 15. Number of treatment-emergent adverse events (TEAEs) 16. Number of treatment-emergent severe or blood glucose confirmed symptomatic hypoglycaemic episodes (week 0-26) 17. Number of treatment-emergent severe or blood glucose confirmed symptomatic hypoglycaemic episodes (week 0-57) 18. Treatment-emergent severe or blood glucose confirmed symptomatic hypoglycaemic episode (yes/no) (week 0-26) 19. Treatment-emergent severe or blood glucose confirmed symptomatic hypoglycaemic episode (yes/no) (week 0-57) 20. Change in biochemistry, amylase 21. Change in biochemistry, lipase 22. Change in biomarker, insulin-like growth factor 1 (IGF-1) 23. Change in biomarker, insulin–like growth factor binding protein 3 (IGFBP 3) 24. Change in hormone, calcitonin 25. Change in hormone, estradiol (for girls) 26. Change in hormone, testosterone (for boys) 27. Change in hormone, prolactin 28. Change in hormone, thyroid stimulating hormone (TSH/thyrotropin) 29. Change in hormone, follicle stimulating hormone (FSH) 30. Change in hormone, luteinizing hormone (LH) 31. Change in hormone, dehydroepiandrosterone sulfate (DHEAS)
32. Anti-semaglutide antibody status. 33. Anti-semaglutide antibody titer. 34. Anti-semaglutide antibodies with in vitro neutralising effect to semaglutide 35. Anti-semaglutide antibodies cross reacting with endogenous GLP-1 36. Cross reacting antibodies with in vitro neutralising effect to endogenous GLP-1
37. Apparent clearance (CL/F) 38. Average concentration (Cavg) 39. Sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC) plasma concentrations |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. From baseline to week 52 2. – 8. From baseline to week 26 and week 52 9. & 10. At week 26 11. & 12. At week 52 13. & 14. Week 0-52 15. Week 0-57 16. Week 0-26 17. Week 0-57 18. At week 26 19. At week 52 20. – 31. From baseline to week 26 and week 52 32. - 36. Week 0-57 37. - 39. Week 0-52 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 20 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Malaysia |
New Zealand |
North Macedonia |
Ukraine |
Taiwan |
Australia |
India |
Israel |
Lebanon |
Mexico |
Morocco |
Russian Federation |
United Kingdom |
United States |
European Union |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | 15 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 9 |
E.8.9.2 | In all countries concerned by the trial days | 15 |